<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333343</url>
  </required_header>
  <id_info>
    <org_study_id>CEGF816X2102</org_study_id>
    <secondary_id>2017-002496-25</secondary_id>
    <nct_id>NCT03333343</nct_id>
  </id_info>
  <brief_title>Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC</brief_title>
  <official_title>A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the
      addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients
      with advanced EGFR-mutant NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase Ib, open label, non-randomized dose escalation study of EGF816 in combination
      with ribociclib, trametinib, or LXH254, followed by dose expansion of EGF816 in combination
      with ribociclib, trametinib, LXH254, INC280, or gefitinib in adult patients with advanced
      EGFR-mutant NSCLC.

      During the dose escalation part, patients will be assigned to the addition of trametinib,
      ribociclib, or LXH254 to EGF816.

      Following determination of the recommended dose for the combination of EGF816 + trametinib,
      EGF816 + ribociclib, and EGF816 + LXH254, patients may be enrolled to the dose expansion arms
      of each of these combinations. Patients may also be assigned to EGF816 + INC280 or EGF816 +
      gefitinib in dose expansion.

      Efficacy assessments will be performed at baseline and every 2 cycles during treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">May 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 21, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events and serious adverse events</measure>
    <time_frame>Every day until study end, approximately 4 years</time_frame>
    <description>Assess safety and tolerability including incidence of dose limiting toxicities, adverse events, and serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR2</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
    <description>Modified objective response rate (ORR2) per RECIST v1.1 (taking as baseline the most recent assessment prior to initiating combination)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
    <description>Overall response rate (ORR) per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
    <description>Time from the date of first dose of study treatment to the date of first documented disease progression (per RECIST v1.1) or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
    <description>Proportion of patients with best overall response of CR, PR, or SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
    <description>Time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">157</enrollment>
  <condition>EGFR-mutant Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816+ trametinib in escalation phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + ribociclib in escalation phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + LXH254 in escalation phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + trametinib in expansion phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + ribociclib in expansion phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + gefitinib in expansion phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + INC280 in expansion phase (patients with known resistance mechanism)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGF816</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trametinib</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribociclib</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LXH254</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed locally advanced (stage
             IIIB) or metastatic (stage IV) EGFR mutant (ex19del, L858R) NSCLC.

          -  Requirements of EGFR mutation status and prior lines of treatment:

          -  Treatment naive patients, who have locally advanced or metastatic NSCLC with EGFR
             sensitizing mutation (e.g., L858R and/or ex19del), have not received any systemic
             antineoplastic therapy for advanced NSCLC and are eligible to receive EGFR TKI
             treatment. Patients with EGFR exon 20 insertion/duplication are not eligible. Note:
             patients who have received only one cycle of chemotherapy in the advanced setting are
             allowed.

          -  Patients who have locally advanced or metastatic NSCLC with EGFR sensitizing mutation
             AND an acquired T790M mutation (e.g., L858R and/or ex19del, T790M+) following
             progression on prior treatment with a 1st-generation EGFR TKI or 2nd-generation EGFR
             TKI. These patients may not have received more than 4 prior lines of antineoplastic
             therapy in the advanced setting, including EGFR TKI, and may not have received any
             agent targeting EGFR T790M mutation (i.e., 3rd-generation EGFR TKI).

          -  Patients who have locally advanced or metastatic NSCLC with EGFR sensitizing mutation
             and a &quot;de novo&quot; T790M mutation (i.e., no prior treatment with any agent known to
             inhibit EGFR including EGFR TKI). These patients may not have received more than 3
             prior lines of antineoplastic therapy in the advanced setting, and may not have
             received any prior 3rd generation EGFR TKI.

          -  Patients must have a site of disease amenable to biopsy, and be a candidate for tumor
             biopsy according to the treating institution's guidelines. Patients must be willing to
             undergo a new tumor biopsy during therapy on this study, and at screening if an
             archival tumor sample obtained since the diagnosis of advanced disease (1L patients)
             or since last treatment failure (2L+ patients) is not available.

        Exclusion Criteria:

          -  Patients with a history or presence of interstitial lung disease or interstitial
             pneumonitis, including clinically significant radiation pneumonitis.

          -  Patients with unstable brain metastases.

          -  Patients with a history of another malignancy.

          -  Patients with a known history of human immunodeficiency virus (HIV) seropositivity.

          -  Patients with clinically significant, uncontrolled heart disease.

          -  Patients participating in additional parallel investigational drug or medical device
             studies.

          -  Prior therapies:

          -  Patients who have been treated with EGFR TKI in the adjuvant setting within 6 months,
             unless acquired EGFR T790M is present in a tumor or blood sample obtained since the
             discontinuation of the EGFR TKI.

          -  Patients who have been treated with prior EGFR TKI targeting T790M (3rd generation).

          -  Patients who have been treated with systemic anti-neoplastic therapy within:

               -  2 weeks for fluoropyrimidine monotherapy

               -  6 weeks for nitrosoureas and mitomycin

               -  4 weeks or â‰¤ 5 half-lives (whichever is shorter) for biological therapy
                  (including monoclonal antibodies) and continuous or intermittent small molecule
                  therapeutics or any other investigational agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Singapore</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR-mutant NSCLC</keyword>
  <keyword>EGF816</keyword>
  <keyword>LXH254</keyword>
  <keyword>INC280</keyword>
  <keyword>ribociclib</keyword>
  <keyword>trametinib</keyword>
  <keyword>gefitinib</keyword>
  <keyword>EGFR T790M</keyword>
  <keyword>BRAF mutation</keyword>
  <keyword>BRAF fusion</keyword>
  <keyword>BRAF rearrangement</keyword>
  <keyword>MET amplification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

